The 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome has been jointly issued by the American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA), and American Society of Nephrology (ASN). This guideline is intended for clinicians managing patients across cardiology, nephrology, endocrinology, and primary care. It retires and replaces the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults, expanding its scope considerably.
These recommendations are designed to help clinicians and individuals identify CKM syndrome risk earlier and take action to protect long-term heart, metabolic, and kidney health. Key Guideline Recommendations CKM Staging and Risk Assessment The guideline outlines four stages of CKM syndrome and reviews…
